New drug combo aims to control tough leukemia with fewer side effects
Disease control
Recruiting now
This study is testing a combination of three drugs (olutasidenib, venetoclax, and azacitidine) for adults newly diagnosed with a specific type of acute myeloid leukemia (AML) that has an IDH1 mutation. The main goals are to see if this combination is safer and works better than t…
Phase: PHASE2 • Sponsor: Justin Watts, MD • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC